欧州連合 - 英語 - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.

カナダ - 英語 - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 500mg - nicotinic acid 500mg - miscellaneous antilipemic agents

カナダ - 英語 - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 750mg - nicotinic acid 750mg - miscellaneous antilipemic agents

カナダ - 英語 - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 1000mg - nicotinic acid 1000mg - miscellaneous antilipemic agents

カナダ - 英語 - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 500mg - nicotinic acid 500mg - miscellaneous antilipemic agents

カナダ - 英語 - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 750mg - nicotinic acid 750mg - miscellaneous antilipemic agents

カナダ - 英語 - Health Canada

sunovion pharmaceuticals canada inc - nicotinic acid - tablet (extended-release) - 1000mg - nicotinic acid 1000mg - miscellaneous antilipemic agents

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - potassium aspartate; magnesium aspartate; nicotinic acid; di-isopropylamine dichloroacetate; sodium selenite; adenosine triphosphate - parenteral liquid/solution/suspension - potassium aspartate amino acid-aspartate active 20.0 mg/ml; magnesium aspartate amino acid-aspartate active 20.0 mg/ml; nicotinic acid alkaloid active 20.0 mg/ml; di-isopropylamine dichloroacetate ungrouped active 50.0 mg/ml; sodium selenite mineral-selenium active 0.5 mg/ml; adenosine triphosphate nucleotide active 2.0 mg/ml - cardiovascular system - dog | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at - vascular system reactant | cardiac stimulant | coronary vasodilator | navicular disease | reactants on vascular system | respiratory stimulant | tick paralysis | vascular system | vasodilation

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

danmot pty ltd - chromium amino acid chelate, quantity: 2 mg; iron, quantity: 200 microgram; riboflavine, quantity: 5 mg; nicotinamide, quantity: 5 mg; zinc, quantity: 4 mg; copper, quantity: 25 microgram; iron amino acid chelate, quantity: 2 mg; manganese amino acid chelate, quantity: 20 mg (equivalent: manganese, qty 2 mg); zinc amino acid chelate, quantity: 20 mg; ginkgo biloba, quantity: 630 microgram (equivalent: ginkgo biloba, qty 5 mg); allium sativum, quantity: 3.57 mg (equivalent: allium sativum, qty 25 mg); sodium molybdate, quantity: 10 microgram (equivalent: molybdenum, qty 3.9 microgram); fucus vesiculosus, quantity: 2 mg (equivalent: fucus vesiculosus, qty 10 mg); crataegus monogyna, quantity: 6.25 mg (equivalent: crataegus monogyna, qty 25 mg); calcium pantothenate, quantity: 30 mg; colecalciferol, quantity: 500 mg; d-alpha-tocopheryl acid succinate, quantity: 60 mg; ascorbic acid, quantity: 200 mg; thiamine hydrochloride, quantity: 10 mg; pyridoxine hydrochloride, quantity: 10 mg; biotin, quantity: 40 microgram; cyanocobalamin, quantity: 10 microgram; folic acid, quantity: 40 microgram; choline bitartrate, quantity: 25 mg; inositol, quantity: 20 mg; dl-methionine, quantity: 20 mg; carnitine, quantity: 5 mg; betacarotene, quantity: 1.5 mg; aminobenzoic acid, quantity: 10 mg; nicotinic acid, quantity: 10 mg; copper amino acid chelate, quantity: 417 microgram; chromium, quantity: 40 microgram; colloidal anhydrous silica, quantity: 5 microgram; bioflavonoids, quantity: 10 mg; cysteine hydrochloride, quantity: 35 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; magnesium stearate; soy polysaccharide; povidone; colloidal anhydrous silica; powdered cellulose; dextrin; ethylcellulose; fractionated coconut oil; alginic acid; hypromellose; iron oxide red; maize starch; silicon dioxide; dl-alpha-tocopherol; sucrose; hydrolysed gelatin; hydrogenated soya oil; ascorbyl palmitate; sodium ascorbate; potable water; calcium phosphate; gelatin - multivitamins, minerals, amino acids and herbal supplement.

カナダ - 英語 - Health Canada

sepracor pharmaceuticals inc - nicotinic acid; lovastatin - tablet (immediate release) - 500mg; 20mg - nicotinic acid 500mg; lovastatin 20mg - hmg-coa reductase inhibitors